DDInter1559 DDInter1435
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Rabeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Rabeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Rabeprazole {u} (Compound) binds {v} (Gene) CYP3A4
Rabeprazole {u} (Compound) downregulates {v} (Gene) THAP11
Rabeprazole {u} (Compound) causes {v} (Side Effect) Fungal skin infection
Rabeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Raltegravir
Rabeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Acetylsalicylic acid
Rabeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Riociguat
Rabeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Indinavir
Rabeprazole {u} may lead to a major life threatening interaction when taken with {v} Neratinib
Rabeprazole (Compound) resembles Lansoprazole (Compound)
Rabeprazole (Compound) resembles Esomeprazole (Compound)
Rabeprazole (Compound) binds CYP3A4 (Gene)
Rabeprazole (Compound) downregulates THAP11 (Gene)
Rabeprazole (Compound) causes Fungal skin infection (Side Effect)
Rabeprazole may cause a minor interaction that can limit clinical effects when taken with Raltegravir
Rabeprazole may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid
Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Indinavir
Rabeprazole may lead to a major life threatening interaction when taken with Neratinib